The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 29, 2016

Filed:

Nov. 23, 2009
Applicants:

Thomas Redelmeier, Vancouver, CA;

Matthias Luz, Mannheim, DE;

Inventors:

Thomas Redelmeier, Vancouver, CA;

Matthias Luz, Mannheim, DE;

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/127 (2006.01); A61K 49/00 (2006.01); A61K 9/00 (2006.01); A61K 31/4745 (2006.01); A61M 25/00 (2006.01);
U.S. Cl.
CPC ...
A61K 49/0084 (2013.01); A61K 9/0019 (2013.01); A61K 9/127 (2013.01); A61K 31/4745 (2013.01); A61K 49/0023 (2013.01); A61K 49/0041 (2013.01); A61M 25/007 (2013.01); A61M 2025/0042 (2013.01);
Abstract

Convection-enhanced delivery (CED) is used as a method to deliver a direct infusion of therapeutic agents to the central nervous center thus circumventing the blood-blood barrier. A non-PEGylated liposomal composition comprising at least one saturated neutral phospholipid and at least one saturated anionic phospholipid and a therapeutic or diagnostic agent encapsulated therein is used to overcome toxicity associated with high peak drug concentration delivered locally CED as well as to increase tissue distribution volume for an improved sustained drug release. In one embodiment, the liposome composition comprises a molar ratio of DSPC:DSPG:CHOL of 7:2:1 and the therapeutic or diagnostic agent is selected from topotecan, conotoxin, gadodiamide or rhodamine, and is used in the treatment of epilepsy.


Find Patent Forward Citations

Loading…